Skip to main content
SpringerLink
Log in

Revisiting the Nelson’s Syndrome: Corticotroph Tumor Progression After Bilateral Adrenalectomy in Cushing’s Disease

  • Chapter
  • First Online:
Cushing's Syndrome

Part of the book series: Contemporary Endocrinology ((COE))

  • 2031 Accesses

Summary

Since Don Nelson’s first description in 1958 of a pituitary macroadenoma occurring after adrenalectomy in a patient with Cushing’s disease, the “Nelson’s syndrome” has long been feared. However, major medical advances, such as pituitary imaging with MRI, surgery by the transsphenoidal route, and safe radiotherapy, have changed the way corticotroph tumor progression (CTP) can be monitored and treated. Rather than “wait” for the late occurrence of Nelson’s syndrome, as defined originally with the complications of macroadenomas, we can now detect, early and precisely, the possible occurrence of CTP long before the classical features of Nelson’s syndrome have developed.

In a recent study of 53 patients followed by MRI after bilateral adrenalectomy, we showed that 3 years after adrenalectomy, the proportion of patients showing evidence of CTP reached 39%; this number tended to plateau at 47% after 7 years. Thus, ca. 50% of the patients showed no evidence of CTP under this time period. Factors that were found to be significantly associated with a higher risk to develop CTP were duration of Cushing’s disease, baseline ACTH plasma level in the year following adrenalectomy, and the rate of increase in ACTH plasma levels after adrenalectomy.

If necessary, pituitary surgery and/or radiotherapy can control the CTP in a majority of situations. The CTP does not seem accelerated during the pregnancy.

There is no question that pituitary surgery remains the first-line treatment in most patients with Cushing’s disease. Yet, when complete removal of a corticotroph tumor is not achievable, total bilateral adrenalectomy can be considered among the various therapeutic options in Cushing’s disease. The CTP is not constant and is manageable in most cases. There is a definite need for new pharmacologic agent directed against corticotroph tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Nelson DH, Meakin JW, Dealy JB, Jr, Matson DD, Emerson K, Jr, Thorn GW. ACTH-producing tumor of the pituitary gland. N Engl J Med 1958;259(4):161–164.

    Article  PubMed  CAS  Google Scholar 

  2. Salassa RM, Kearns TP, Kernohan JW, Sprague RG, Maccarty CS. Pituitary tumors in patients with Cushing’s syndrome. J Clin Endocrinol Metab 1959;19:1523–1539.

    Article  PubMed  CAS  Google Scholar 

  3. Montgomery DA, Welbourn RB, McCaughey WT, Gleadhill CA. Pituitary tumours manifested after adrenalectomy for Cushing’s syndrome. Lancet 1959;2:707–710.

    Article  PubMed  CAS  Google Scholar 

  4. Glenn F, Karl RC, Horwith M. The surgical treatment of Cushing’s syndrome. Ann Surg 1958;148(3):365–374.

    Article  PubMed  CAS  Google Scholar 

  5. Rees JR, Zilva JF. Diabetes insipidus complicating total adrenalectomy. J Clin Pathol 1959;12:530–534.

    Article  PubMed  CAS  Google Scholar 

  6. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932;50:137–195.

    Google Scholar 

  7. Nelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing’s syndrome. Ann Intern Med 1960;52:560–569.

    PubMed  CAS  Google Scholar 

  8. Assié G, Bahurel H, Bertherat J, Kujas M, Legmann P, Bertagna X. The Nelson’s syndrome… revisited. Pituitary 2004;7(4):209–215; review.

    Article  PubMed  Google Scholar 

  9. Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J Clin Endocrinol Metab 2007;92(1):172–179.

    PubMed  Google Scholar 

  10. Juliani G, Avataneo T, Potenzoni F, Sorrentino T. [CT and MR compared in the study of hypophysis]. Radiol Med (Torino) 1989;77(1–2):51–64.

    CAS  Google Scholar 

  11. Johnson MR, Hoare RD, Cox T, et al. The evaluation of patients with a suspected pituitary microadenoma: computer tomography compared to magnetic resonance imaging. Clin Endocrinol (Oxf) 1992;36(4):335–338.

    Article  CAS  Google Scholar 

  12. Vest-Courtalon C, Ravel A, Perez N, et al. [Pituitary gland MRI and Cushing disease: report of 14 operated patients]. J Radiol 2000;81(7):781–786.

    PubMed  CAS  Google Scholar 

  13. Bahurel-Barrera H, Assie G, Silvera S, Bertagna X, Coste J, Legmann P. Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing’s disease patients followed up after bilateral adrenalectomy. Pituitary 2008;11(3):263–269.

    Article  PubMed  Google Scholar 

  14. Jornayvaz FR, Assié G, Bienvenu M, Coste J, Legmann P, Bertherat J, Bertagna X. Pregnancy does not accelerate corticotroph tumor progression in Nelson’s syndrome. Endocrine Society Annual Meeting 2009, P1–P610.

    Google Scholar 

  15. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009;94(1):223–230.

    PubMed  CAS  Google Scholar 

  16. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94(1):115–122.

    PubMed  CAS  Google Scholar 

  17. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002;8(11):1281–1287.

    Article  PubMed  CAS  Google Scholar 

  18. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001;108(8):1123–1131.

    PubMed  CAS  Google Scholar 

  19. Bertagna X, Raux-Demay MC, Guilhaume B, et al. Cushing’s disease. In: Melmed S, (ed) The Pituitary. 2nd edition. Malden: Blackwell, 2002:496–560.

    Google Scholar 

  20. de Keyzer Y, Bertagna X, Lenne F, et al. Proopiomelanocortin gene expression in ACTH secreting non-pituitary tumors. J Clin Invest 1985;76:1892–1898.

    Article  PubMed  CAS  Google Scholar 

  21. Raffin-Sanson ML, de Keyzer Y, Bertagna X. Proopiomelanocortin, a polypeptide precursor with multiple functions: from physiology to pathological conditions. Eur J Endocrinol 2003;149(2):79–90; review

    Article  PubMed  CAS  Google Scholar 

  22. Dahia PL, Grossman AB. The molecular pathogenesis of corticotroph tumors. Endocr Rev 1999;20(2):136–155.

    Article  PubMed  CAS  Google Scholar 

  23. de Keyzer Y, Rene P, Lenne F, Auzan C, Clauser E, Bertagna X. V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. Horm Res 1997;47(4–6):259–262; review.

    Article  PubMed  CAS  Google Scholar 

  24. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71(6):1427–1433.

    Article  PubMed  CAS  Google Scholar 

  25. Gicquel C, Le Bouc Y, Luton JP, Girard F, Bertagna X. Monoclonality of corticotroph macroadenomas in Cushing’s disease. J Clin Endocrinol Metab 1992;75(2):472–475.

    Article  PubMed  CAS  Google Scholar 

  26. Wolfsen AR, Odell WD. The dose-response relationship of ACTH and cortisol in Cushing’s disease. Clin Endocrinol (Oxf) 1980;12(6):557–568.

    Article  CAS  Google Scholar 

  27. Suda T, Tozawa F, Dobashi I, Horiba N, Ohmori N, Yamakado M, Yamada M, Demura H. Corticotropin-releasing hormone, proopiomelanocortin, and glucocorticoid receptor gene expression in adrenocorticotropin-producing tumors in vitro. J Clin Invest 1993;92(6):2790–2795.

    Article  PubMed  CAS  Google Scholar 

  28. Resetic J, Reiner Z, Ludecke D, Riznar-Resetic V, Sekso M. The effects of cortisol, 11-epicortisol, and lysine vasopressin on DNA and RNA synthesis in isolated human adrenocorticotropic hormone-secreting pituitary tumor cells. Steroids 1990;55(3):98–100.

    Article  PubMed  CAS  Google Scholar 

  29. Dahia PL, Honegger J, Reincke M, et al. Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. J Clin Endocrinol Metab 1997;82(4):1088–1093.

    Article  PubMed  CAS  Google Scholar 

  30. Nolan LA, Levy A. Temporally sensitive trophic responsiveness of the adrenalectomized rat anterior pituitary to dexamethasone challenge: relationship between mitotic activity and apoptotic sensitivity. Endocrinology 2003;144(1):212–219.

    Article  PubMed  CAS  Google Scholar 

  31. Karl M, Von Wichert G, Kempter E, et al. Nelson’s syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996;81(1):124–129.

    Article  PubMed  CAS  Google Scholar 

  32. Huizenga NA, de Lange P, Koper JW, et al. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus. J Clin Endocrinol Metab 1998;83(3):917–921.

    Article  PubMed  CAS  Google Scholar 

  33. Carey RM, Varma SK, Drake CR, Jr, et al. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing’s syndrome. A clinical, morphologic, and biochemical study. N Engl J Med 1984;311(1):13–20.

    Article  PubMed  CAS  Google Scholar 

  34. Gertz BJ, Contreras LN, McComb DJ, Kovacs K, Tyrrell JB, Dallman MF. Chronic administration of corticotropin-releasing factor increases pituitary corticotroph number. Endocrinology 1987;120(1):381–388.

    Article  PubMed  CAS  Google Scholar 

  35. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. Development of Cushing’s syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992;130(6):3378–3386.

    Article  PubMed  CAS  Google Scholar 

  36. de Keyzer Y, Rene P, Beldjord C, Lenne F, Bertagna X. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol (Oxf) 1998;49(4):475–482.

    Article  CAS  Google Scholar 

  37. Dieterich KD, Gundelfinger ED, Ludecke DK, Lehnert H. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1998;83(9):3327–3331.

    Article  PubMed  CAS  Google Scholar 

  38. McNicol AM, Carbajo-Perez E. Aspects of anterior pituitary growth, with special reference to corticotrophs. Pituitary 1999;1(3–4):257–268.

    Article  PubMed  CAS  Google Scholar 

  39. Wynn PC, Harwood JP, Catt KJ, Aguilera G. Regulation of corticotropin-releasing factor (CRF) receptors in the rat pituitary gland: effects of adrenalectomy on CRF receptors and corticotroph responses. Endocrinology 1985;116(4):1653–1659.

    Article  PubMed  CAS  Google Scholar 

  40. Sakai K, Horiba N, Sakai Y, Tozawa F, Demura H, Suda T. Regulation of corticotropin-releasing factor receptor messenger ribonucleic acid in rat anterior pituitary. Endocrinology 1996;137(5):1758–1763.

    Article  PubMed  CAS  Google Scholar 

  41. Hornyak M, Weiss MH, Nelson DH, Couldwell WT. Nelson syndrome: historical perspectives and current concepts. Neurosurg Focus 2007;23(3):E12.

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors are indebted to Stéphane Gaillard (Neurosurgery Department, Hôpital Foch), Hélène Bahurel, Marie Bienvenue, Paul Legmann (Radiology Department, Hôpital Cochin), Bertrand Dousset (Endocrine Surgery, Hôpital Cochin), and Michèle Kujas (Pathology Department, Hôpital La Pitié).

Author information

Authors and Affiliations

  1. Service des Maladies Endocriniennes et Métaboliques, Centre de Référence des Maladies Rares de la Surrénale, INSERM U-567, Institut Cochin, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris 5, Paris, France

    Guillaume Assie & Xavier Bertagna MD

  2. Service des Maladies Endocriniennes et Métaboliques, Faculté de Médecine Centre de Référence des Maladies Rares de la Surrénale, INSERM U-567, Institut Cochin, Hôpital Cochin, Paris Descartes, Université Paris 5, Paris, France

    Laurence Guignat

  3. Service des Maladies Endocriniennes et Métaboliques, Centre de Référence des Maladies Rares de la Surrénale, INSERM U-567, Institut Cochin, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris 5, 27, rue Fg St Jacques, 75014, Paris, France

    Jérôme Bertherat

Authors
  1. Guillaume Assie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence Guignat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jérôme Bertherat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xavier Bertagna MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Division of Endocrinology and Metabolism, Hospital das Clínicas, University of Sao, Sao Paulo, 05403-000, Brazil

    Marcello D. Bronstein

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Assie, G., Guignat, L., Bertherat, J., Bertagna, X. (2010). Revisiting the Nelson’s Syndrome: Corticotroph Tumor Progression After Bilateral Adrenalectomy in Cushing’s Disease. In: Bronstein, M. (eds) Cushing's Syndrome. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-449-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-449-4_15

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-448-7

  • Online ISBN: 978-1-60327-449-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation